LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 51.32 USD -0.74% Market Closed
Market Cap: 2.8B USD
Have any thoughts about
LivaNova PLC?
Write Note

LivaNova PLC
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LivaNova PLC
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
LivaNova PLC
NASDAQ:LIVN
Capital Expenditures
-$49.6m
CAGR 3-Years
-27%
CAGR 5-Years
-9%
CAGR 10-Years
-17%
Smith & Nephew PLC
LSE:SN
Capital Expenditures
-$432m
CAGR 3-Years
0%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Capital Expenditures
-ÂŁ5.3m
CAGR 3-Years
-20%
CAGR 5-Years
-21%
CAGR 10-Years
-6%
Angle PLC
LSE:AGL
Capital Expenditures
-ÂŁ388k
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Capital Expenditures
-ÂŁ1.7m
CAGR 3-Years
-39%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Capital Expenditures
-$4.5m
CAGR 3-Years
-56%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
No Stocks Found

LivaNova PLC
Glance View

Market Cap
2.8B USD
Industry
Health Care

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

LIVN Intrinsic Value
81.64 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is LivaNova PLC's Capital Expenditures?
Capital Expenditures
-49.6m USD

Based on the financial report for Sep 30, 2024, LivaNova PLC's Capital Expenditures amounts to -49.6m USD.

What is LivaNova PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-17%

Over the last year, the Capital Expenditures growth was -59%. The average annual Capital Expenditures growth rates for LivaNova PLC have been -27% over the past three years , -9% over the past five years , and -17% over the past ten years .

Back to Top